We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Investors aren’t happy with the steps Allergan has taken to try to remedy its share-price slump—and they’re calling on outsiders to help stir things up.